作者:Zijun Chen、Gianluca Destro、Florian Guibbal、Chung Ying Chan、Bart Cornelissen、Véronique Gouverneur
DOI:10.1021/acs.orglett.1c02770
日期:2021.9.17
poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation. The most successful approach features an aldehydic boronic ester precursor that is subjected to reductive amination post-18F-labeling and affords [18F]rucaparib
聚(ADP-核糖)聚合酶(PARP)抑制剂rucaparib在临床上用于治疗BRCA突变的癌症。在此,我们报告了两种通过应用铜介导的亲核18 F-氟脱硼来获得 rucaparib 的18 F-同位素体的策略。最成功的方法是采用醛硼酸酯前体,在18 F 标记后进行还原胺化,得到 [ 18 F]rucaparib,其活性产率为 11% ± 3% ( n = 3) 和摩尔活性 ( A m ) 高达 30 GBq/μmol。提出了初步体外研究。